The University of Chicago Header Logo

Connection

Jay Koyner to Complement Inactivating Agents

Back to Details
This is a "connection" page, showing publications Jay Koyner has written about Complement Inactivating Agents.
Jay Koyner
Connection Strength
0.232
Complement Inactivating Agents
  1. A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). Trials. 2025 May 30; 26(1):181.
    View in: PubMed
    Score: 0.232
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.